Compounded medications are not equivalent to and should not be considered generics of FDA-approved drug products
GLP-1 receptor agonists have emerged as a transformative class of medications for weight management, with clinical trials showing an average weight loss of 15-22% body weight over 68 weeks
Such risks and uncertainties include, but are not limited to, those related to patient enrollment, the effectiveness of Buntanetap, and the timing, effectiveness, and anticipated results of the Company's clinical trials evaluating the efficacy, safety, and tolerability of Buntanetap
Rabbit anti-Ki67 monoclonal antibodies (D2H10, Cell Signaling Technology) were used at 1:800 dilution
How GLP-1 and Dual GIP/GLP-1 Agonists Work to Treat Obesity GLP-1 agonists and dual GIP/GLP-1 agonists are medications that increase satiety (the feeling of fullness), slow digestion, and quiet constant thoughts about food (known as food noise), making it easier to lose weight and keep it off
Its effect on abdominal fat reduction also contributes to improved metabolic health
